[go: up one dir, main page]

WO2004089414A3 - Combinations of proton pump inhibitors or blockers with prokinetic agents - Google Patents

Combinations of proton pump inhibitors or blockers with prokinetic agents Download PDF

Info

Publication number
WO2004089414A3
WO2004089414A3 PCT/BR2004/000046 BR2004000046W WO2004089414A3 WO 2004089414 A3 WO2004089414 A3 WO 2004089414A3 BR 2004000046 W BR2004000046 W BR 2004000046W WO 2004089414 A3 WO2004089414 A3 WO 2004089414A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug
proton pump
blockers
combinations
prokinetic agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/BR2004/000046
Other languages
French (fr)
Other versions
WO2004089414A2 (en
Inventor
Negrao Alexandre Funari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medley Farmaceutica Ltda
Original Assignee
Medley Farmaceutica Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medley Farmaceutica Ltda filed Critical Medley Farmaceutica Ltda
Publication of WO2004089414A2 publication Critical patent/WO2004089414A2/en
Publication of WO2004089414A3 publication Critical patent/WO2004089414A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention refers to a drug combination, drug association, a drug, and a drug presenting a facilitated presentation comprising, individually, and at the same time, jointly: one or more drug units containing on or more proton pump inhibitor agents; one or more drug units containing one or more prokinetic agents; and optionally, other additives or drugs which are well-known to those skilled in the art, within a medium or excipient, also pharmaceutically acceptable, preferably used for the treatment of functional dyspepsia and gastroesophageal reflux disease.
PCT/BR2004/000046 2003-04-08 2004-03-31 Combinations of proton pump inhibitors or blockers with prokinetic agents Ceased WO2004089414A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI0301179-8 2003-04-08
BR0301179 2003-04-08

Publications (2)

Publication Number Publication Date
WO2004089414A2 WO2004089414A2 (en) 2004-10-21
WO2004089414A3 true WO2004089414A3 (en) 2004-12-16

Family

ID=33136632

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2004/000046 Ceased WO2004089414A2 (en) 2003-04-08 2004-03-31 Combinations of proton pump inhibitors or blockers with prokinetic agents

Country Status (1)

Country Link
WO (1) WO2004089414A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0303794A (en) * 2003-09-05 2005-04-12 Medley S A Ind Farmaceutica Medication, Medication Kit, Medication Set, Medication Association and Medication Presenting Facilitated Presentation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0803251A1 (en) * 1996-04-23 1997-10-29 Janssen Pharmaceutica N.V. Immediate release pH-independent solid dosage form of cisapride
WO2000051584A2 (en) * 1999-03-02 2000-09-08 Sepracor Inc. Methods and compositions using (-) norcisapride in combination with proton pump inhibitors or h2 receptor antagonists
WO2003097011A1 (en) * 2002-05-17 2003-11-27 Eisai Co., Ltd. Compositions and methods using proton pump inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0803251A1 (en) * 1996-04-23 1997-10-29 Janssen Pharmaceutica N.V. Immediate release pH-independent solid dosage form of cisapride
WO2000051584A2 (en) * 1999-03-02 2000-09-08 Sepracor Inc. Methods and compositions using (-) norcisapride in combination with proton pump inhibitors or h2 receptor antagonists
WO2003097011A1 (en) * 2002-05-17 2003-11-27 Eisai Co., Ltd. Compositions and methods using proton pump inhibitors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANON.: "Refluxkrankheit der Speiseröhre und peptisches Ulkus", FORTSCHRITTE DER MEDIZIN, vol. 116, no. 34, 1998, pages 35 - 38, XP008037882 *
BEERS ET AL, EDS.: "The Merck Manual of Diagnosis and Therapy", 1999, MERCK RESEARCH LABORATORIES, WHITEHOUSE STATION, NJ, USA, XP002303226 *
DE MORHAES-FILHO AND CHINZON: "Doença do refluxo gastroesofagico", REV. BRAS. MED., vol. 51, 1994 - 1995, pages 112 - 124, XP008037884 *
MATHESON AND JARVIS: "Lansoprazole - an update of its place in the management of acid-related disorders", DRUGS, vol. 61, no. 12, 2001, pages 1801 - 1833, XP008037879 *
MONES ET AL: "Criteria used by general practitioners in prescribing prokinetic or antisecretory drugs in patients with functional dyspepsia", REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, vol. 93, no. 5, 2001, pages 287 - 292, XP008037880 *
THJODLEIFSSON: "Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors", DRUGS AGING, vol. 19, no. 12, 2002, pages 911 - 927, XP008037878 *

Also Published As

Publication number Publication date
WO2004089414A2 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
WO2005082414A3 (en) Concomitant drugs of a sulfonamide and another therapeutic agent
WO2005044199A3 (en) Combination of proton pump inhibitor and sleep aid
TW200716678A (en) Administration of HCV protease inhibitors in combination with food to improve bioavailability
WO2006071762A3 (en) Pyrimidine-based inhibitors of dipeptidyl peptidase iv and methods
WO2005105780A3 (en) Compositions useful as inhibitors of rock and other protein kinases
ITBO20030062A1 (en) CAPSULE USED FOR THE PREPARATION OF AN INFUSED BEVERAGE.
DE60236541D1 (en) INHIBITORS OF 11-BETA-HYDROXYSTEROIDDEHYDROGENASE TYPE 1
TW200716157A (en) Pharmaceutical formulations and methods of treatment using the same
WO2006041773A3 (en) Lactam compounds useful as protein kinase inhibitors
WO2007093450A3 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
WO2004030611A3 (en) Non-nucleoside reverse transcriptase inhibitors
WO2007106317A3 (en) Pharmaceutical combinations of hcv-protease and -ires inhibitors
WO2005105088A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
UA101313C2 (en) Normal;heading 1;heading 2;heading 3;WEEKLY ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
MXPA05003253A (en) Novel pyrimidineamide derivatives and the use thereof.
WO2006058007A3 (en) Jnk inhibitors for treatment of cns injury
EA200401515A1 (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING FLIBANSERIN IN POLYMORPHIC MODIFICATION A
WO2004071374A3 (en) Once a day orally administered pharmaceutical compositions
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors
WO2005016249A3 (en) Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ace inhibitor for the treatment of central nervous system damage
WO2005075471A3 (en) Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
WO2008009802A3 (en) Drugs comprising an inhibitor of class 1 alpha mannosidase for the treatment of sarcoglycanopathies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase